Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1682 | HIT-exercise Wiki | 0.45 |
| drug3086 | Primary care professionals reports of potential patient safety incidents, non-COVID-19 related Wiki | 0.45 |
| drug2797 | PT-X and IMT Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009133 | Muscular Atrophy NIH | 0.45 |
| D001284 | Atrophy NIH | 0.45 |
| D001281 | Atrial Fibrillation NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003202 | Skeletal muscle atrophy HPO | 0.45 |
| HP:0004757 | Paroxysmal atrial fibrillation HPO | 0.22 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 5 clinical trials
This expanded access program will provide access to COVID-19 convalescent plasma 150 or more individuals with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such manifestations at participating hospitals in Colorado.COVID-19 convalescent plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19. Convalescent plasma collected from individuals who have recovered from COVID-19 contains antibodies to SARS-CoV-2. Preliminary evidence and data collected during other respiratory virus outbreaks (including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic) suggest that the antibodies in convalescent plasma may be effective in fighting the infection.
Older age is an independent poor outcome predictor among COVID-19 hospitalized patients . Among 72,314 COVID-19 cases, case fatality rate (CFR) was 2.3% in total population, 8% in people aged 70 to 79, and 14.8% in those aged 80 and older. In the whole population, CFR was higher in people with comorbidities, ranging from 5-6% in persons with hypertension, chronic respiratory disease, diabetes or cancer, up to 10% in those with cardiovascular diseases. Sars-CoV-2 seems to be able to induce a functional exhaustion of specified T and NK lymphocyte subpopulations, breaking down antiviral immunity. One possible explanation is that the immune system of elderly people, might be exhausted by chronic stimulation associated with comorbidities and more susceptible to this Sars-CoV-2 effect. As a result, in these patients, the activation of the innate immune system might fail to produce an adequate adaptive response (i.e., virus-specific CD8+ T-cells). This results in persistent self-induced inflammation that eventually causes mortality. The investigators hypothesize that transfusing convalescent plasma (containing neutralizing antibodies) at an early phase of COVID-19 infection could prevent or switch off the persistent inflammatory response elicited by the virus. The objective of this study are: - To demonstrate the superiority of COVID-19 convalescent plasma (CCP) plus standard therapy (ST) over ST alone - To prevent progression of pneumonia in COVID-19 patients aged ≥65 with chronic comorbidities - To decrease viral load - To raise anti-SARS-CoV-2 antibody titer in recipients
Description: Proportion of patients without progression in severity of pulmonary disease defined as worsening of 2 points in the ordinal scale of WHO within day 14
Measure: Rate of COVID-19 progression Time: days 1 to 14.The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients' health when they are sick with COVID-19.
Description: Cumulative incidence of serious adverse events (SAEs) at Study Day 29.
Measure: Participants with serious adverse events. Time: Up to 29 days from treatment.Description: Survival and time to clinical improvement as measured by removal from mechanical ventilation.
Measure: Time to clinical improvement. Time: Up to 60 days from receiving treatment.Description: Time to improvement of one category and two categories from Day 1.
Measure: Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment, daily while hospitalized until discharge or death and on Days 15, 22, and 29.Description: Time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.
Measure: Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment, daily while hospitalized until discharge or death and on Days 15 and 29.Description: Incidence of new oxygenation use up to Day 29.
Measure: Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Days of new oxygen use up to Day 29.
Measure: Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Oxygen-free days to Day 29.
Measure: Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Days of non-invasive ventilation/high flow oxygen up to Day 29.
Measure: Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Incidence of non-invasive ventilation up to Day 29.
Measure: Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Days of non-invasive ventilation/high flow oxygen up to Day 29.
Measure: Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Ventilation/ECMO free days up to Day 29.mechanical ventilation or ECMO use during the study.
Measure: Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Incidence of new mechanical ventilation or ECMO use up to Day 29.
Measure: Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Days of new mechanical ventilation or ECMO use up to Day 29.
Measure: Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006. Time: From enrollment to Day 29.Description: Duration of hospitalization.
Measure: Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006 Time: To Day 29.Description: D14 and D28 mortality.
Measure: Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006 Time: To Day 28.Description: Cumulative incidence of SAEs through Day 29.
Measure: Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29.
Measure: Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in WBC with differential on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in hemoglobin measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in platelets measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.. Time: Through Day 29.Description: Changes in creatinine measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.. Time: Through Day 29.Description: Changes in glucose measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in bilirubin measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006.. Time: Through Day 29.Description: Changes in ALT measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in AST measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.Description: Changes in PT measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006. Time: Through Day 29.The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
Description: Cumulative incidence of serious adverse events (SAEs) at Study Day 29.
Measure: Participants with serious adverse events. Time: Up to 29 days from treatmentDescription: Severity is measured by the 8-point ordinal clinical severity scale at D29 where 1 is the best state to be in and 8 is the worst (equals death).
Measure: Comparison of clinical severity score between patients on the experimental versus control arms; Time: Up to 29 days from treatmentDescription: Time to recovery, defined by time to levels 1-3 on the ordinal scale
Measure: Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms Time: Up to 29 days from treatmentDescription: Time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.
Measure: Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment, daily while hospitalized until discharge or death and on Days 15 and 29.Description: Oxygen-free days to Day 29.
Measure: Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29Description: Incidence of new oxygenation use up to Day 29.
Measure: Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Days of new oxygen use up to Day 29.
Measure: Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Days of non-invasive ventilation/high flow oxygen up to Day 29
Measure: Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Incidence of non-invasive ventilation up to Day 29.
Measure: Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Days of non-invasive ventilation/high flow oxygen up to Day 29
Measure: Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Ventilation/ECMO free days up to Day 29. mechanical ventilation or ECMO use during the study.
Measure: Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Incidence of new mechanical ventilation or ECMO use up to Day 29.
Measure: Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Days of new mechanical ventilation or ECMO use up to Day 29.
Measure: Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms Time: From enrollment to Day 29.Description: Duration of hospitalization.
Measure: Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms Time: To Day 29Description: D14 and D28 mortality.
Measure: Mortality of convalescent plasma administration by comparing treatment vs control arms Time: To Day 28Description: Cumulative incidence of SAEs through Day 29.
Measure: Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29.
Measure: Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Changes in WBC with differential on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Changes in hemoglobin measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Changes in platelets measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29.Description: Changes in creatinine measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29.Description: Changes in glucose measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29.Description: Changes in bilirubin measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Changes in ALT measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29Description: Changes in AST measurement on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29.Description: Changes in PT measurement laboratory adverse events on Days 1, 3, 5, 8, and 11 (while hospitalized); Days 15 and 29 (if attends in person visit or still hospitalized).
Measure: Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms Time: Through Day 29.This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports